Telzuit Medical Technologies, Inc. (Telzuit Medical), formerly Taylor Madison Corp., incorporated on September 26, 2001, is focused on researching, developing and marketing ambulatory medical devices, which monitor, measure and record physiological signals generated by the body. Its initial product will be its Bio-Patch Wireless Holter Monitor (the Bio-Patch) a 12-lead, wireless holter heart monitor, which measures, records and transmits physiological signals associated with a patient's cardiovascular system. The Company discontinued all operations, during the fiscal year ended June 30, 2005, and became a shell company, exploring the viability of acquiring an operating company. In April 2005, Taylor Madison Corp. formed a wholly owned subsidiary, Taylor Madison Holdings Inc. On May 6, 2005, the Company acquired Telzuit Technologies, Inc. from Telzuit Technologies, LLC. On August 18, 2005, it changed its name from Taylor Madison Corp. to Telzuit Medical Technologies, Inc. Bio-Patch Wireless Holter Monitor In December 2004, Telzuit Medical completed the design, fabrication and testing of a pre- production model of its first product for commercialization, its battery-operated, digital 12 lead Bio-Patch Wireless Holter Monitor. The Bio-Patch System has a substantial amount of technical computer hardware, as well as advanced database software, Philips Medical's United States Food and Drug Administration (FDA)-approved algorithm and a cellular telephone-personal digital assistant (PDA) with specially designed software, all of which communicate to transmit, receive and store a patient's biometric heart data. The Bio-Patch is an ambulatory patient heart monitor and recording system that allows a patient's heart to be continuously monitored over a period of 24 to 48 hours while the patient carries out his or her daily activities away from the physician's office or hospital. The Bio-Patch is comprised of a disposable bandage-like strip, which is imbedded with lead sensory connectors. A battery attached to the strip activates the lead sensory connectors to transmit heart activity information. The battery life lasts between 24 and 48 hours, at which time the patient must discard the old patch and replace it with a new one. The Company is designing a communication system as an intranet, through which data collected by the Bio-Patch System can be transmitted through any form of cellular technology. The Bio-Patch captures electrical impulses of the patient's heart and transmits this information to a cellular telephone-like device that the patient carries. This device (the Unit) measures and records the electrical activity of the patient's heart. Information transmitted by each Unit will be routed through cellular towers to a switching station maintained at Telzuit Medical's corporate offices. The Company has licensed computer software that will monitor the heart activity of patients wearing its Bio-Patch. This software, which has been developed by Philips Medical and other medical service providers, can detect irregular heart activity. Patients using the Bio-Patch will be able to move around freely while data is collected and sent in near real time from the patient module to the monitoring center. At the conclusion of the recording period, the patient returns the Unit to the cardiologist. The patient's information, having been sent via cell phone to the monitoring center, is then analyzed by the Philips' algorithm. After the prescribing period, the physician is able to access the patient information via secure Web portal and download raw data and a report. The physician then interprets all of the information available to him or her to make a diagnosis. The Bio-Patch System is entirely diagnostic and is not intended to be a life-saving device. Bio-Patch Sleep Apnea Device Telzuit Medical has filed an application with the FDA for approval of a new sleep apnea device based on the Bio-Patch wireless system. As of June 30, 2005, Sleep apnea affected an estimated 12 to 25 million people in the United States. Elderly